ArriVent BioPharma Ownership | Who Owns ArriVent BioPharma?


OverviewForecastFinancialsChart

ArriVent BioPharma Ownership Summary


ArriVent BioPharma is owned by 109.69% institutional investors, 2.77% insiders. Suvretta capital management is the largest institutional shareholder, holding 11.44% of AVBP shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 5.62% of its assets in ArriVent BioPharma shares.

AVBP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArriVent BioPharma109.69%2.77%-12.46%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.80%11.85%52.35%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management4.40M11.44%$101.53M
Infinitum asset management4.15M10.79%$95.72M
Hhlr advisors3.93M10.22%$90.64M
Orbimed advisors3.03M7.87%$69.84M
Fmr3.02M7.84%$69.58M
Blackrock funding, inc. /de2.53M6.58%$58.37M
Octagon capital advisors lp1.97M5.12%$45.47M
Novo1.94M5.05%$44.81M
Vanguard group1.87M4.46%$37.61M
Sofinnova investments1.70M4.41%$39.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
General catalyst group management1.49M18.79%$34.48M
Infinitum asset management4.15M11.95%$95.72M
Hhlr advisors3.93M5.42%$90.64M
Octagon capital advisors lp1.97M5.03%$45.47M
Novo1.94M3.63%$44.81M
Suvretta capital management4.40M2.59%$101.53M
Vivo capital885.92K1.71%$20.44M
Sofinnova investments1.70M1.49%$39.14M
Orbimed advisors3.03M1.39%$69.84M
Fund 1 investments499.99K1.32%$11.53M

Top Buyers

HolderShares% AssetsChange
Vivo capital885.92K1.71%885.92K
Point72 asset management748.20K0.02%531.53K
Balyasny asset management426.28K0.01%383.25K
Logos global management lp350.00K0.40%350.00K
State street1.42M0.00%329.44K

Top Sellers

HolderShares% AssetsChange
Siren---700.00K
Fmr3.02M0.00%-687.44K
Cormorant asset management, lp---585.46K
Citadel advisors166.16K0.00%-292.35K
Franklin resources---256.42K

New Positions

HolderShares% AssetsChangeValue
Vivo capital885.92K1.71%885.92K$20.44M
Logos global management lp350.00K0.40%350.00K$8.07M
Nomura242.05K0.01%242.05K$5.58M
Vanguard fiduciary trust217.13K0.00%217.13K$5.01M
Polymer capital management (hk)122.28K0.24%122.28K$2.82M

Sold Out

HolderChange
Ifp advisors-1.00
Clearstead advisors-1.00
Montag a & associates-11.00
Principal securities-16.00
Parkside financial bank & trust-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202614318.18%42,190,2885.19%1091.20%9126.39%28-17.65%
Dec 31, 202580-25.23%13,197,905-65.78%310.37%46-26.98%2531.58%
Sep 30, 20251058.25%38,570,31714.70%1101.19%6326.00%18-40.00%
Jun 30, 20259615.66%33,618,96315.59%961.30%498.89%3042.86%
Mar 31, 20257-91.14%11,264,335-59.25%350.53%4-92.98%--100.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
HBM Healthcare Investments AG Ord2.55M5.62%346.15K
Fidelity Select Biotechnology1.56M3.45%-116.50K
Vanguard Total Stock Mkt Idx Inv1.16M2.55%-
State Street® SPDR® S&P® Biotech ETF783.30K1.73%-5.56K
iShares Russell 2000 ETF756.51K1.67%6.39K
Fidelity Growth Compy Commingled Pl S448.34K0.99%592.00
Vanguard Institutional Extnd Mkt Idx Tr344.09K0.76%6.02K
Fidelity Growth Company Fund324.04K0.72%-
Fidelity Small Cap Growth298.74K0.66%-
Fidelity Small Cap Index289.95K0.64%3.62K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 10, 2025HILLHOUSE INVESTMENT MANAGEMENT, LTD.-Sell$12.98M
Jan 30, 2024HILLHOUSE INVESTMENT MANAGEMENT, LTD.-Buy$10.00M
Jan 30, 2024ORBIMED ADVISORS LLC Buy$4.00M
Jan 30, 2024GORDON CARL L Buy$4.00M
Jan 30, 2024HEALY JAMES-Buy$8.00M

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4-1
2025 Q3--
2025 Q2--
2024 Q14-

AVBP Ownership FAQ


Who Owns ArriVent BioPharma?

ArriVent BioPharma shareholders are primarily institutional investors at 109.69%, followed by 2.77% insiders and -12.46% retail investors. The average institutional ownership in ArriVent BioPharma's industry, Biotech Stocks , is 35.80%, which ArriVent BioPharma exceeds.

Who owns the most shares of ArriVent BioPharma?

ArriVent BioPharma’s largest shareholders are Suvretta capital management (4.4M shares, 11.44%), Infinitum asset management (4.15M shares, 10.79%), and Hhlr advisors (3.93M shares, 10.22%). Together, they hold 32.44% of ArriVent BioPharma’s total shares outstanding.

Does Blackrock own ArriVent BioPharma?

BlackRock is not among the top 10 institutional shareholders of ArriVent BioPharma.

Who is ArriVent BioPharma’s biggest shareholder by percentage of total assets invested?

General catalyst group management is ArriVent BioPharma’s biggest shareholder by percentage of total assets invested, with 18.79% of its assets in 1.49M ArriVent BioPharma shares, valued at 34.48M$.

Who is the top mutual fund holder of ArriVent BioPharma shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of ArriVent BioPharma shares, with 5.62% of its total shares outstanding invested in 2.55M ArriVent BioPharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools